Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 15,619 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin and Connective Tissue Disease Clear all

Conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Hormone Receptor Positive Tumor
Interventions: RLY-5836, Fulvestrant, Palbociclib, Ribociclib, Abemaciclib; Drug
Lead sponsor: Relay Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Orlando, Florida • Indianapolis, Indiana • Boston, Massachusetts + 4 more

Conditions: Dermatomyositis
Interventions: Prednisone, Methotrexate, Etanercept; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 4 Years to 16 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Breast Cancer
Interventions: Capecitabine, Bevacizumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Seattle, Washington • Tacoma, Washington

Conditions: Breast Cancer
Interventions: The Survivor Stories Tablet; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 30 Years and older · Female only
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Vitiligo
Interventions: Dermabrasion-Micrografting, Dermabrasion; Device · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: 49-channel optical spectrometer; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 485 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Breast Cancer
Interventions: therapeutic autologous dendritic cells, trastuzumab, vinorelbine ditartrate; Biological · Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Breast Cancer, Colorectal Cancer, Pain
Interventions: Capecitabine, Celecoxib, Radiation Therapy, Placebo; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 13
States / cities: Santa Rosa, California • Grand Rapids, Michigan • Kalamazoo, Michigan + 10 more

Conditions: Alopecia Areata
Interventions: CycloSPORINE Injectable Product, Saline Solution; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate, Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
Interventions: SYS6043; Drug
Lead sponsor: Conjupro Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Plantation, Florida • Austin, Texas • San Antonio, Texas + 1 more

Conditions: Breast Cancer
Interventions: Questionnaires and Focus Group; Other
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Psoriasis, Inflammation
Interventions: Inflammatory markers; Diagnostic Test
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 99 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Atopic Dermatitis, Eczema
Interventions: Tralokinumab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: Female only
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2035
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Psoriasis, Alopecia Areata, Polymorphous Light Eruption
Interventions: Lumiton yarn sleeve, Lumiton yarn hat, Lumiton yarn shirt; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Skin Cancer
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 10 Years and older
Enrollment: 1,889 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2026
U.S. locations: 4
States / cities: Basking Ridge, New Jersey • Harrison, New York • Hauppauge, New York + 1 more

Conditions: Psoriasis
Interventions: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 34
States / cities: Birmingham, Alabama • Anaheim, California • Bakersfield, California + 31 more

Conditions: Melanoma, Liver Metastasis
Interventions: Nab-Paclitaxel (Abraxane); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Malignant Melanoma
Interventions: GM-CSF; Drug
Lead sponsor: Mt. Sinai Medical Center, Miami; Other
Eligibility: 16 Years to 90 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Miami Beach, Florida • Atlanta, Georgia

Conditions: Colorectal Cancer, Breast Cancer
Interventions: Mammography direct mail coupled with a financial incentive, Usual care, Colonoscopy direct mail coupled with a financial incentive; Behavioral
Lead sponsor: Minnesota Department of Health; Government
Eligibility: 50 Years to 74 Years
Enrollment: 138,554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Breast Cancer
Interventions: HER-2/neu peptide vaccine; Biological
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer, Pain, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions: assessment of therapy complications, cognitive assessment, psychosocial assessment and care; Procedure
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 2,310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 32
States / cities: Chicago, Illinois • Evanston, Illinois • Elkhart, Indiana + 19 more

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic HER2-Low Breast Carcinoma, Metastatic HER2-Positive Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma, Unresectable HER2-Low Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma, Unresectable Hormone Receptor-Positive Breast Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Triple-Negative Breast Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan, Pidnarulex, Radiologic Imaging Procedure, Trastuzumab Deruxtecan; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • St Louis, Missouri

Conditions: Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Other Autoimmune Disease
Interventions: Nitroglycerin, Topical AmphiMatrix; Drug
Lead sponsor: MediQuest Therapeutics; Industry
Eligibility: 15 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 17
States / cities: Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more

Search by objective public record fields.

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis

Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model

Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy

Survivor Stories: Impact on Cancer Patients' Quality of Life and Follow-up

A New Micrografting Technique for Vitiligo

An Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients

Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer

Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer

Intralesional Cyclosporine for Alopecia Areata

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

MammoVerse: Breast Cancer Sexual Health Focus Groups

Regulation of Inflammatory Genes in Psoriasis

Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

Improving Disease Severity

In Vivo Confocal Microscopy of Cutaneous Neoplasms and Normal Skin

A Phase 3 Study in Participants With Moderate to Severe Psoriasis

Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver

Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma

Promoting Cancer Screening Among Medicaid Recipients in Minnesota

HER-2 Protein Vaccine in Treating Women With Breast Cancer

Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon